How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance document for consultation.docx

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about pembrolizumab

Marketing authorisation indication

2.1

Pembrolizumab (Keytruda, Merck Sharp and Dohme), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for 'the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS of 1 or more'.

Price

2.3

The list price of pembrolizumab is £2,630 per 100 mg per 4 ml vial (excluding VAT; BNF online accessed November 2023).

2.4

The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.